Allscripts Healthcare Stock
Allscripts Healthcare Stock
A loss of -2.780% shows a downward development for Allscripts Healthcare.
The community is currently still undecided about Allscripts Healthcare with 2 Buy predictions and 0 Sell predictions.
With a target price of 11 € there is a hugely positive potential of 57.14% for Allscripts Healthcare compared to the current price of 7.0 €.
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allscripts Healthcare | -2.780% | -2.778% | -4.110% | -35.185% | -24.324% | -49.275% | -19.159% |
| MicroVision Inc | 1.540% | 1.061% | -22.305% | -75.568% | -57.767% | -91.814% | 37.272% |
| Fonar Corp. New | -1.420% | -0.714% | -6.711% | -13.125% | -21.469% | -6.081% | -19.186% |
| Fluidigm Corp. | 0.870% | 0.870% | 2.655% | 8.411% | 12.621% | -50.501% | - |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at TD Cowen from $26.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat